S&P 500
5.070,55 +59,95 (+1,20%) Nasdaq
15.696,64 +245,33 (+1,59%) NIKKEI 225
37.552,16 +113,55 (+0,30%) Dólar/Euro
1,0704 +0,0048 (+0,45%) Petróleo Brent
88,35 +1,35 (+1,55%) Bitcoin EUR
61.772,22 -548,71 (-0,88%)
Endonovo Therapeutics, Inc. (ENDV)
Endonovo Therapeutics, Inc.
6320 Canoga Avenue
15th Floor
Woodland Hills, CA 91367
United States
800 489 4774
https://www.endonovo.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Alan Brian Collier | Chairman & CEO | 300k | N/A | 1966 |
| Mr. Don Calabria | Vice President of Operations | N/A | N/A | N/A |
| Mr. Garry Michael Kann | Head of Corporate Development | N/A | N/A | N/A |
| Mr. Ira Weisberg | President & Chief Commercial Officer of Medical Division | N/A | N/A | 1949 |
Descripción
Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.
Gobierno corporativo
El ISS Governance QualityScore de Endonovo Therapeutics, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
